Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Side-effects news

Show

From To
Tenofovir, boosted atazanavir and boosted lopinavir are associated with cumulative risk of developing chronic kidney disease

Three antiretroviral drugs are associated with a slowly increasing rate of chronic kidney disease over time, the Conference on Retroviruses and Opportunistic Infections (CROI 2015) in

Published
27 February 2015
By
Gus Cairns
Tenofovir alafenamide equally effective but safer for kidneys and bones than current formulation

Tenofovir alafenamide (TAF), a new formulation that has lower concentrations in the blood but reaches higher levels in cells, is as effective as the older version, tenofovir disoproxil

Published
27 February 2015
By
Liz Highleyman
HIV Organizations Urge Continuation of D:A:D Study

D:A:D follows 50,000 HIV-positive people, looking at drug safety and side effects over time. Results from D:A:D have changed HIV treatment guidelines, and how HIV-positive people are treated by their health care providers. We urge pharmaceutical companies to continue funding this vital study.

Published
11 February 2015
From
Treatment Action Group
Antiretroviral Neurotoxicity May Cause Cognitive Problems

As many as 50% of those on combination antiretroviral therapy (cART) suffer from mild to moderate cognitive dysfunction. Antiretroviral medications themselves may be partly to blame for such neurocognitive problems, suggests a recent review of previous studies. But the authors of this review do not recommend that antiretroviral treatment be stopped.

Published
28 January 2015
From
The Body Pro
HIV—Pregnancy-related issues

Themed issue of CATIE's magazine Treatment Update, with several articles on the safety of antiretrovirals during pregnancy.

Published
20 January 2015
From
CATIE
Zimbabwe finally switches away from stavudine

The Zimbabwean government has finally dropped stavudine, lamivudine and nevirapine as its first-line HIV therapy in favour of a single dose treatment which has a combination of three drugs, namely tenofovir/lamivudine/efavirenz (TLN).The Government dropped the first line HIV treatment after realizing that it was causing severe side effects on patients. Stanley Takaona of the Zimbabwe HIV and AIDS Activist Union Community Trust said the introduction of the new HIV drug was going to save more lives.

Published
19 January 2015
From
AllAfrica
Dramatic decline in risk for heart attacks among HIV-positive Kaiser Permanente members

Previously reported increased risk of heart attacks among HIV-positive individuals has been largely reversed in recent years for Kaiser Permanente's California patients, according to a study published in the current online issue of Clinical Infectious Diseases. The adjusted risk ratio for heart attacks among HIV-positive study participants went from an 80 percent increased risk in 1996 to no increased risk in 2010-2011. Reported first on Aidsmap at http://www.aidsmap.com/Heart-attack-risk-in-people-with-HIV-may-be-falling-but-not-in-women/page/2834402/ .

Published
19 January 2015
From
Eurekalert
Viral Load Reductions Persist With Less Efavirenz for HIV

The virologic responses with reduced-dose efavirenz at 48 weeks have proven durable out to 96 weeks, ENCORE1 study results show.

Published
07 November 2014
From
Medscape (requires free registration)
Inflammatory markers associated with development of diabetes in people taking HIV therapy

Low-level elevations in important markers of systemic inflammation are associated with the development of type-2 diabetes in people taking antiretroviral therapy (ART), investigators report in the online edition

Published
20 October 2014
By
Michael Carter
IDWeek 2014: AbbVie 3D HCV Regimen Well-tolerated in PEARL Trials

AbbVie's 3D hepatitis C regimen containing paritaprevir (ABT-450), ombitasvir, and dasabuvir was generally well-tolerated in the Phase 3 PEARL trials, according to a pooled analysis presented at IDWeek 2014 last week in Philadelphia. Serious side effects were uncommon and few people discontinued treatment for this reason.

Published
16 October 2014
From
HIVandHepatitis.com
← First12345...71Next →

Filter by country